Bioreactor-Cultured Human iPSC Cardiomyocyte Clusters Promote Long-Term Primate Myocardial Repair

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  Nature Communications https://doi.org/10.1038/s41467-026-77103-0
Dr. Ina Gruh et al.

Points

Hanover Medical School and German Primate Centre researchers evaluated human induced pluripotent stem cell derived cardiomyocyte aggregates in a macaque model of myocardial infarction.
Three month post transplantation evaluations demonstrated that bioreactor cultured cell aggregates formed extensive structured human muscle grafts within damaged non human primate cardiac tissue.
Functional recovery and early transient arrhythmogenicity correlated directly with the intrinsic in vitro electrophysiological and contractile properties of individual pluripotent stem cell lines.
Overexpression of a red fluorescent reporter protein dysregulated cellular conduction and contraction machinery providing mechanistic insight into optimizing stem cell therapies for clinical translation.
Authors concluded that functional pre screening of stem cell aggregates supports autologous transplantation strategies to repair damaged human hearts without lifelong immunosuppression medication.

Summary

This study evaluated the therapeutic efficacy, electrophysiological safety, and structural engraftment of human induced pluripotent stem cell-derived cardiomyocyte aggregates (hiCMAs) in a non-human primate model of myocardial infarction. Published in Nature Communications by researchers from Hanover Medical School (MHH) and the German Primate Centre, the investigation addressed critical challenges in cardiac regenerative medicine following severe cardiomyocyte loss and chronic heart failure. Given that adult human cardiomyocytes lack intrinsic regenerative capacity, the research sought to determine whether intramyocardial injection of bioreactor-cultured hiCMA spherical clusters promotes long-term structural repair, functional hemodynamic recovery, and mechanical integration in Javanese macaques (Macaca fascicularis).

The preclinical study compared hiCMAs generated from two distinct human iPSC cell lines, evaluating graft survival, arrhythmogenicity, and contractile recovery across a three-month post-transplantation period under immunosuppressive therapy. Histological and functional evaluations at three months revealed that both iPSC lines formed extensive, structured human cardiac muscle grafts within the infarcted primate myocardium. However, functional hemodynamic recovery and sustained contractile improvements correlated directly with the intrinsic in vitro electrophysiological and contractile properties of specific iPSC clones. Notably, transplant recipients experienced transient graft-induced ventricular arrhythmias during early post-operative phases, which progressively attenuated over time. Mechanistic evaluation utilizing a red fluorescent reporter iPSC line (“Amber”) revealed that reporter protein overexpression disrupted intrinsic cellular conduction and contraction machinery without impeding overall engraftment capacity.

The authors conclude that intramyocardial transplantation of bioreactor-cultured hiCMAs represents a viable therapeutic strategy for long-term myocardial repair and functional recovery. The strong correlation between in vitro contractile force assays and in vivo functional outcomes highlights the critical necessity of pre-transplantation functional screening for cell lines. Furthermore, these findings support ongoing efforts to transition toward autologous hiCMA therapies derived from patient-specific blood cells, eliminating the requirement for lifelong immunosuppressive regimens while establishing a translational framework for human cardiac stem cell trials.

Link to the article: https://www.nature.com/articles/s41467-026-77103-0

References

Gruh, I., Martens, A., Cebotari, S., Schrod, A., Haase, A., Halloin, C., Triebert, W., Kriedemann, N., Goecke, T., Arar, M., Hoeffler, K., Frank, P., Lampe, K., Moussavi, A., Kuleshova, A., Hradil, V., Fricke, V., Szepes, M., Mätz-Rensing, K., … Martin, U. (2026). Human iPSC-cardiomyocyte-aggregate cell therapy in non-human primates and correlation of heart recovery with contractile and electrophysiological cardiomyocyte properties. Nature Communications, 17(1), 9066. https://doi.org/10.1038/s41467-026-77103-0